Smith & Nephew plc (NYSE:SNN) Shares Bought by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. lifted its stake in shares of Smith & Nephew plc (NYSE:SNN - Free Report) by 63.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 112,859 shares of the medical equipment provider's stock after purchasing an additional 43,924 shares during the period. Crossmark Global Holdings Inc.'s holdings in Smith & Nephew were worth $3,515,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of SNN. Argonautica Private Wealth Management Inc. boosted its holdings in Smith & Nephew by 6.3% in the 2nd quarter. Argonautica Private Wealth Management Inc. now owns 10,244 shares of the medical equipment provider's stock worth $254,000 after buying an additional 605 shares during the period. First Trust Direct Indexing L.P. boosted its holdings in Smith & Nephew by 6.9% in the 3rd quarter. First Trust Direct Indexing L.P. now owns 9,659 shares of the medical equipment provider's stock valued at $301,000 after purchasing an additional 626 shares during the period. Inspire Advisors LLC boosted its holdings in Smith & Nephew by 3.0% in the 2nd quarter. Inspire Advisors LLC now owns 22,286 shares of the medical equipment provider's stock valued at $552,000 after purchasing an additional 639 shares during the period. Rhumbline Advisers boosted its holdings in Smith & Nephew by 8.6% in the 2nd quarter. Rhumbline Advisers now owns 10,365 shares of the medical equipment provider's stock valued at $257,000 after purchasing an additional 819 shares during the period. Finally, Janney Montgomery Scott LLC boosted its holdings in Smith & Nephew by 13.8% in the 1st quarter. Janney Montgomery Scott LLC now owns 9,611 shares of the medical equipment provider's stock valued at $244,000 after purchasing an additional 1,165 shares during the period. Hedge funds and other institutional investors own 25.64% of the company's stock.

Smith & Nephew Price Performance

Shares of NYSE:SNN traded down $0.07 during midday trading on Tuesday, reaching $24.67. 769,649 shares of the company were exchanged, compared to its average volume of 864,909. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11. The business's fifty day moving average is $29.24 and its two-hundred day moving average is $27.87. Smith & Nephew plc has a one year low of $23.65 and a one year high of $31.72.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on SNN. Deutsche Bank Aktiengesellschaft downgraded shares of Smith & Nephew from a "buy" rating to a "hold" rating in a report on Friday, November 1st. Berenberg Bank lowered shares of Smith & Nephew from a "buy" rating to a "hold" rating in a research note on Wednesday, November 6th. Finally, StockNews.com upgraded shares of Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research note on Monday, August 5th. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy".

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.